Background: The objective of this study is to systematically review the literature on economic evaluations of interventions for the early diagnosis of Alzheimer's disease (AD) and related disorders and to describe their general and methodological characteristics. We focused on the diagnostic aspects of the decision models to assess the applicability of existing decision models for the evaluation of the recently revised diagnostic research criteria for AD.
INTRODUCTION
Alzheimer's disease (AD) and other dementing disorders are common in the elderly, with a worldwide prevalence estimated in 2010 at 35.6 million, which will increase to 115.4 million in 2050. AD has a substantial impact on the person who suffers from the disease, his or her family, and society [1] and [2] . The total worldwide cost of AD and other dementing disorders was estimated at $604 billion in 2010 [3] .
Earlier diagnosis and early intervention are considered important mechanisms to manage the worldwide impact of the disease. Early diagnosis can be described as a "timely" recognition of mild dementia in response to a patient's complaints to ensure that disabled individuals receive the necessary support and care or as the "symptomatic predementia" diagnosis when cognition is impaired but functioning not yet affected (typically referred to as mild cognitive impairment) [4] .
Until recently, the diagnosis of AD was largely based on clinical judgment using the NINCDS-ADRDA criteria [5] . These criteria were recently revised [6] , [7] and [8] to enhance diagnostic accuracy and enable an early diagnosis even when only very mild clinical symptoms are present. Biomarkers in cerebrospinal fluid (CSF), positron emission tomography (PET), magnetic resonance imaging (MRI), and photon emission tomography (SPECT) are attributed a more prominent role in the new diagnostic research criteria. However, validation of these research criteria is needed before the role of new biomarkers can be adopted in clinical practice [9] .
The ultimate goal of diagnostic testing is to guide disease management to improve patient outcomes and patient well-being. Tests that lack this potential are considered obsolete [10] and [11] . Furthermore, because health-care resources are scarce and must be allocated efficiently, decision-makers require evidence of the cost-effectiveness of diagnostic tests before adoption in clinical practice. Such evidence can be generated by decision-analytic models which are defined as a set of mathematical relationships that form a structure reflecting the natural progression of a disease. By simulating patient cohorts, these models enable the estimation of the likelihood of each consequence and its corresponding costs and effects [12] and [13] . Trial-based economic evaluations, in which costs and health-care outcomes are measured during clinical trials, can also provide evidence of cost-effectiveness.
Decision-analytic models of AD have been reviewed extensively by Cohen et al [14] . However, this review only included models that project disease progression, excluding possible relevant evidence on the evaluation of diagnostic techniques. Furthermore, the applicability of existing decision models to evaluate the recently revised research criteria has not been elaborated. This raises the urgent need for a review of economic evaluations of diagnostic interventions for AD.
The objective of this study was to systematically review the literature on economic evaluations of interventions for the early diagnosis of AD and related disorders and to describe their general and methodological characteristics. Using these results, recommendations for future studies were focused on the diagnostic aspects of the decision models to assess the applicability of existing decision models for the evaluation of the recently revised diagnostic research criteria for AD.
PubMed and the National Institute for Health Research Economic Evaluation Database databases [17] and [18] were searched through March 2011. Medical subject headings and free text words on dementia, diagnosis, and economic evaluation were used to identify relevant English-language articles with an available abstract (see Appendix 1 for the full search query). Two reviewers (R.H. and C.W.) independently assessed titles. A title was excluded if both reviewers agreed that it explicitly met one of the exclusion criteria. The same reviewers independently assessed abstracts of the remaining titles. An abstract was excluded if either reviewer considered that it did not meet all five inclusion and exclusion criteria. Dissimilarities in the reviewers' assessments were resolved by discussion. The full article was assessed if the remaining abstracts had dissimilarities that could not be otherwise resolved. If an article was not accessible, the author was contacted to request a copy of the original publication. A third reviewer (J.S.) resolved the remaining differences in the reviewer's assessments; this third reviewer made the final decision as to whether the article would be included. See Appendix 2 for an overview of the study selection process.
Analyses
General study characteristics of all of the included articles are described in Table 1 . For modeling studies, the model type was scored separately for the diagnostic and treatment part of the model. A Markov model is characterized by mutually exclusive disease states that represent the possible consequences of the options under evaluation. Disease progression is reflected by the transition of a patient's disease states over discrete time periods [12] . We used the term "state-independent" for mathematical models that apply a fixed time cycle similar to a Markov model but reflect the disease progression on a continuous scale and not by mutually exclusive disease states, such as the MMSE categories mild AD (MMSE 21-26), moderate AD (MMSE [14] [15] [16] [17] [18] [19] [20] , moderately severe AD (MMSE [10] [11] [12] [13] [14] , and severe AD (MMSE <10). If the treatment was only summarized in one or more fixed outcome values and was not represented by a mathematical model, it was scored as "static". Buxton et al [19] described five different roles of modeling in an economic evaluation that we used to classify all of the modeling studies: extrapolating beyond data observed in trial, linking the intermediate (clinical) endpoints to final outcomes, generalizing to other settings, synthesizing head-to-head comparisons where relevant trials do not exist, and informing decisions in the absence of hard data.
Methodological characteristics of the trial-based economic evaluations were assessed using the Consensus on Health Economic Criteria (CHEC) list [20] (see Table 2 ). Methodological characteristics of the modeling studies were assessed using the framework for quality assessment of decisionanalytic models [21] and [22] (see Table 3 ), which includes three key themes: structure, data, and consistency. Questions S3.2, S3.3, and S8 required expert knowledge in the field of AD and were clarified by a psychiatrist (F.V.). Furthermore, the framework is most likely intended for treatment interventions, although diagnostic interventions are the focus of this review and required adjustment of the items D2b1 and D2b2 that are described in Table 3 . Two reviewers (C.W. and R.H.) independently performed analyses. In one case, one of the reviewers was the author of the paper being assessed; therefore, this reviewer was replaced by another reviewer (P.A.) to ensure objectivity. Dissimilarities in scoring were resolved by discussion. If discussion was not successful, a third reviewer (J.S.) determined the final score. Both of the checklist questions were answered with "yes" if both reviewers agreed that the study paid sufficient attention to an item, "no" if the item was not fulfilled or if insufficient information was available to assess the item, or "N/A" (not applicable) if the question was either not applicable to the study or if it referred to a previous question scored as "no". A summary score for each article was not applied because this quantitative scoring system was not considered to be sufficiently reliable and valid as a means of quality assessment. Therefore, a qualitative summary is provided to better distinguish major from minor methodologic flaws.
RESULTS
The search retrieved 2109 titles, of which 90 did not have an abstract available, 84 were duplicates, and an additional 180 were not in English. From the remaining 1755 titles, 936 were excluded based on the exclusion criteria. Of the remaining 819 titles, 735 were excluded after reading the abstracts, leaving 84 articles for assessment by R.H. and C.W. After reading the full articles, they excluded 75 articles on the basis of the exclusion criteria, of which 2 were assessed by the third reviewer (J.S.) because a decision could not be made through discussion between R.H. and C.W. Thus, a total of nine studies [23] , [24] , [25] , [26] , [27] , [28] , [29] , [30] and [31] were included in the review. Fig. 1 displays a flowchart of the inclusion and exclusion process. Three articles [24] , [25] and [26] analyzed a combination of two models of which the treatment part was published in a different article [32] and [33] . To fully evaluate the model, this publication was also included for assessment. Furthermore, the economic evaluation in two articles [25] and [26] was based on the same model and a similar situation applies to references 27 and 28. If the articles referred to one another the information from the referenced article was also used to assess the article for this review. Table 1 provides an overview of the study characteristics. The studies can be divided into two categories on the basis of their objective. The first consists of three studies evaluating early diagnoses, which are strategies aimed at preventing underdiagnosis (i.e., timely recognition of patients suffering from dementia) to bring forward treatment. Although gained treatment effects in patients who would otherwise be undiagnosed were evaluated, the impact of an incorrect diagnosis (i.e., a false positive or false negative test outcome) was not included [23] , [24] and [30] . The second category consists of six studies evaluating a specific diagnostic test or imaging strategy. Except for the trial-based study, a disease progression model was applied to describe costs and effects of true-and false-positive and -negative diagnostic pathways [25] , [26] , [27] , [28] , [29] and [31] .
Diversity among the study characteristics was considerable on several items. Strategies under evaluation varied from specific imaging techniques to multidisciplinary assessments. Population ranged from non-demented patients with early symptoms to moderate dementia evaluated in * Part of the model was described in Getsios et.al. [32] † Part of the model was described in Neuman et.al. [33] ‡ Model type was valued as "static" if not represented by a mathematical model (e.g., when the effect was summarized in one or more fixed outcome values) § Model types were based on Buxton et.al. [19] ¶ Additional strategies evaluated in a sensitivity analysis are not stated Table 2 displays the application of the CHEC list [20] on the trial-based economic evaluation. A time horizon of 1 year was considered too short for the inclusion of all relevant costs and consequences and generalizability was insufficiently addressed. Abbreviations: N, the item was not fulfilled or insufficient information was available in the article to assess the item; Y, both reviewers agreed that the study paid sufficient attention to an item Table 3 displays the results of the quality assessment using the framework for decision-analytic models [21] . Twenty framework items required scoring by the third reviewer (J.S.); two were due to dissimilarities between the two reviewers that could not be resolved by discussion. Items in several topics were not fulfilled or were insufficiently addressed by most included studies. The following four were also considered of importance regarding this review's focus on the diagnostic aspects of the decision models. Model scope was considered insufficiently addressed because a lifetime horizon was disregarded and the population and setting were mostly not addressed. The options under evaluation were considered not fulfilled because many studies did not evaluate all feasible options or did not justify their exclusion, especially regarding combinations of diagnostic tests. Further, several items of the data identification were not addressed sufficiently, especially regarding the identification of key parameters. Lastly, according to the checklist, all types of uncertainty analyses were considered not described or not performed by almost all included studies. Abbreviations: N, item was not fulfilled or insufficient information was available; N/A, not applicable to the study or referred to a previous question scored with "N"; Y, both reviewers agreed sufficient attention was paid to an item. * According to the framework, the model scope should include the perspective, involved technologies, population, setting, and time horizon at the outset of the study. † This item required expert knowledge in the field of AD. The structure of a model was therefore considered consistent with a coherent theory of AD if it included the following basic elements in the diagnostic process: history taking, examination of cognition, and structural imaging [43, 44] . Additionally, if treatment was included, it had to reflect cognition and a progressive decline according to a clinical measurement scale [14, 45] (e.g., the Mini-Mental State Examination (MMSE) or Clinical Dementia Rating). ‡ This item required expert knowledge in the field of AD. As stated in the introduction, new research criteria assigning to biomarkers a fundamental role in the diagnostic process have recently been developed. Applying these research criteria to the diagnostic process is considered a competing theory regarding model structure. § This item required expert knowledge in the field of AD. The underlying biological process was considered appropriate if disease states or pathways reflected cognition. ¶ This item was changed to derivation of diagnostic accuracy. # This item was changed to extrapolation of diagnostic accuracy, according to its relevance within the hierarchical model of diagnostic efficacy [46] . ** Information to score the item was only retrieved from the additional publication that described part of the model
DISCUSSION
The objective of the present study was to systematically review the literature on economic evaluations of interventions for the early diagnosis of AD and related disorders and to describe their methodological characteristics. Eight decision-analytic modeling studies and one trial-based economic evaluation were retrieved. Study quality was assessed using the framework for decisionanalytic models [21] and the CHEC list [20] , and overall the results reflect considerable methodological quality. However, population and diagnostic setting (scope), interventions under evaluation, selection and quality assessment of key diagnostic input parameters, and uncertainty analyses were not fulfilled or were insufficiently addressed by most included studies. Although the study conclusions were considered valid given the data presented, the diversity in study characteristics and methodology could have a major impact on the cost-effectiveness estimate and do not allow for a valid comparison of the cost-effectiveness outcomes.
We discuss the applicability of the diagnostic part of existing decision models for the economic evaluation of the recently revised diagnostic research criteria for AD. Two aspects were considered of major importance as indicated by the framework for diagnostic test evaluation by Van den Bruel et al [11] .
The first aspect regards diagnostic test accuracy, which is highly dependent on patient population characteristics, clinical setting and (patient selection by) results of previously performed tests [10] . Most studies left the above aspects insufficiently described (i.e.: the scope was minimally addressed). Because the newly developed research criteria are targeted on various disease severity in specialized centers, it is important to specify the corresponding targeted population and setting in decision analyses to enable their evaluation. Furthermore, most studies limited the diagnostic options under evaluation and minimally addressed sensitivity analyses to evaluate alternative diagnostic scenarios. Therefore, possible diagnostic strategies such as using biomarkers as add-on or triage were insufficiently evaluated. Furthermore, the newly developed research criteria divide the AD biomarkers into two categories (biomarkers of β-Amyloid deposition and of neuronal injury) and emphasized the importance of evaluating different combinations. This was insufficiently explored by the options under evaluation or by the sensitivity analyses. Questions on optimal decision-making when biomarker results contradict or when to stop testing were not answered.
The second aspect refers to the impact on patient outcome. Most studies in this review included only the impact of pharmacological treatment, which, in our opinion, underexposes the possible nonmedical effects in symptomatic predementia patients. Because current treatment guidelines do not advise medication in this disease phase and nonpharmacological treatments are mainly aimed at dementia-related symptoms [34] , it leaves the diagnostic test impact mainly to nonmedical aspects [35] , such as anxiety, depression, psychological well-being, (financial) decision-making, and future care planning [4] , [36] and [37] ).
Recommendations
Following these findings, three recommendations for future decision models to enable the evaluation of the new diagnostic research criteria can be made. First, we advise to describe in detail the model scope, including the intended goal as timely diagnosis or symptomatic predementia diagnosis, the population and clinical setting characteristics regarding disease state at the moment of diagnosis, and what diagnostic tests already have been performed in the population. We advise to describe these items separately as targeted by the decision model and as applied in the retrieved (literature) evidence on key diagnostic parameters such as test sensitivity and specificity.
Second, we advise to include a variety of possible test combinations as options under evaluation or to address these by structural sensitivity analyses (e.g., the study of McMahon et al [26] ). At last, we recommend representing the diagnostic strategy by a decision tree, including probabilities for each test outcome and their corresponding non-medical consequences, followed by a Markov model or discrete event simulation describing long-term disease progression [38] (for example as applied by two of the included studies [25] and [26] ).
Limitations
Both the CHEC-list for trial-based economic evaluations and the framework for quality assessment of decision-analytic models support the assessment of studies for a review. Judgments, however, remain subjective and therefore the use of three reviewers was adopted for this evaluation. We recommend that such a procedure be used for future studies. Also, several items in the framework for decision-analytic models were interpreted in different ways and therefore required resolution by a third reviewer (JS).
Furthermore, items including harm of testing, willingness to undergo a test, consequences of (false) diagnosis, purpose of testing regarding screening, diagnosis and prognosis, and place in the clinical pathway regarding other tests that have been performed are important in diagnostic test evaluation. However, major flaws on these items were not differentiated to minor flaws by using the quality assessment checklists. We applied a qualitative summary to enable such distinction though ideally a quantitative score would be applied that combines the different constructs of a model and assessed their relative importance to rate the quality of the studies.
Non-medical consequences of testing in the absence of direct clinical benefits are considered important. Quality of life scales are potentially useful though rarely capture all possible test effects and therefore specific instruments are advised to capture the nonmedical effects [35] . Retrieving quality of life estimates will be a challenge for future research. Meanwhile, willingness to pay estimates can, despite of challenges in obtaining reliable estimates, help to isolate the non-medical value [39] . Neumann et al [40] found that on average people are willing to pay about $450 for an AD test in absence of treatment and that a positive test result influences future planning in part of the subjects. If non-medical consequences could not be quantified they should be assessed qualitatively.
By excluding screening or risk assessment instruments we have not elaborated on the applicability of current decision models for the evaluation of the recently revised criteria for the presymptomatic pre-dementia phase. These criteria are however indicated as "strictly for research purposes only" and at this moment less relevant to evaluate for applicability in clinical practice.
Overall, the reviewers found that insufficient information was available for the assessment of all items of the framework for decision-analytic models, thereby increasing uncertainty about the interpretation and generalizability of the results. However, the quantity of publishable information is restricted by journal word count limits. The space available to describe all relevant aspects in detail is limited, especially for economic evaluations of diagnostic interventions, which most likely include both a diagnostic intervention and treatment options. A practical solution currently is to include an extensive appendix, as demonstrated by the model of Getsios et al [32] and, in a different field, by Van Gestel et al [41] .
Issues of implementation were not included in the assessment instruments, though they may be of importance in assessing economic evaluations of diagnostic interventions for AD [16] . MRI and PET scans (and the production of PET tracers), for example, are not available in all hospitals. As a result, additional logistic effort or the reorganization of services may be necessary.
All included studies have been performed before the publication of the revised criteria and obviously therefore have not necessarily adopted the preferred model scope or methodology to compare a variety of test combinations. An example of an ongoing study adopting such scope and taking account the recommendations from this review is the LeARN study [42] (clinicaltrials.gov/ct2/show/NCT01450891) from which the results will be available in 2013.
Conclusion
A systematic review of economic evaluations of interventions for the early diagnosis of AD and related disorders was conducted with the aim of describing their general and methodological characteristics. The search retrieved eight decision-analytic modeling studies and one trial-based economic evaluation. The overall results reflect considerable methodological quality. However, diversity among the study objective and characteristics was considerable and the topics scope, options under evaluation, data identification and uncertainty analyses were not fulfilled or insufficiently addressed. To apply current decision models for the assessment of the recently revised diagnostic research criteria for AD we recommend to describe in detail the model scope, to include a variety of possible test combinations as options under evaluation, and to apply an explicit quality of life estimate to reflect the impact of non-medical aspects.
